Evaluation of the Effect of Double Inhibition of Angiotensin II AT1 Receptor and Neprilysin Activity on Sympathic Nervous System Activity in Patient With Heart Failure
Phase of Trial: Phase IV
Latest Information Update: 22 May 2017
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Heart failure
- Focus Pharmacodynamics
- Acronyms B2AN-SNS
- 17 May 2017 Status changed from not yet recruiting to recruiting.
- 16 Aug 2016 Planned initiation date changed from 1 May 2016 to 1 Oct 2016.
- 15 Jun 2016 New trial record